IRLAB Therapeutics AB (publ)

Welcome to a quarter presentation with the research company E-Lab Therapeutics in view of the first quarter of 2026. E-Lab researches on Parkinson's disease and addresses both the disease as such and the different symptoms. Christina Torfgård, CEO, Nicholas Waters Senior Vice President, R&D, and Gustav Albert, CFO, will present results and activities, followed by a Q&A session with analysts and your investment questions. Let me greet the CEO, Christina Torfgård. Welcome.

Thank you, Mattias. I would like to welcome you to today's broadcast. an anledning av Q1, kvartal 1 som vi nu har släppt idag. Jag tänker att vi går vidare till den första bilden. Kan vi ta vidare? Här har vi vår disclaimer. Vi är ju listade på Nasdaq huvudmarknaden. Vi går vidare, tack. Här har vi dagens agenda. Jag kommer att gå igenom some events that have happened during the period and after the end of the period. Then I will hand over to Gustav Albert who will present the financial situation and what has happened during the period. And it will of course be focused on the business emission that we just went out and communicated yesterday. So I hope you will find it interesting. Then we have R&D, as Nicholas Waters will present what has happened in the different projects. And finally, I will summarize and then we have Q&A. Then we can take the next picture, thank you. This period has been really good, we have had many events. We have brought some of them in this picture. First of all, we have for 757, our medical candidate that we develop for parties that have which we do in collaboration with MSR Yotsuka. There we have started the study and in February we took in and dose the first individual in this study, which meant that after that we have the right to non-stop payments of 3 million US dollars, which will be paid out during 2026. This means that 757 continues according to the plan, the project, Vi ser fram emot att kunna läsa av resultaten under nästa år. Vi har Pripymat som är den kandidaten som vi utvecklar mot fall och fallskador. Här har vi presenterat data tidigare och under perioden så var vårt företagrepresentanter nere på ADPD, ett stort internationellt möte inom Alzheimers och Parkinson. and presented this data. It was of great interest, both scientifically from researchers, but also from various pharmaceutical companies. So this strengthened the case for our medical candidate, Piripimat, when we take it further. We also presented two other posters, one that concerned the platform itself, Integrative Screening Process, where it was of great interest. And then we had another poster, which was about dyskinesia. and the use of amandadine. We also had a lot of interest in that. Then yesterday we went out and communicated that we will carry out a project with over-dividing of 68 million in total on the the company's emissions and 34 on the over-dividing part. So in total, we will be able to get up to 102 million Swedish kronor. And we are incredibly grateful for the support that we see already today. And that will give Gustav more information on what it means. Then during the period, the election preparation was also presented. that we propose two new candidates to sit in our board, and they are Jan Backman and James Gangort. We are very happy that the proposals, they bring with them many years of experience working at various pharmaceutical companies, so we look forward to having them in the board. With that, I think we'll move on to the next picture, and I'll hand it over to Gustav.

Hi. We can take the next pictures. We have released our Q1 just today, and as Kristina mentioned, we have received a milestone in the Q1. And if you look at the net sales, it says 39 million. It's 27 million, this milestone, which has 3 million. And then it's a replacement for the running parts related to 757. If you look at... cash flow, which is important. We have in the cash flow 51 million, and then we have cash flow from operating activities. So if you look at the period's cash flow change, which is 32 million, it is important to point out that if you were to analyze it in a little more detail, you can divide it up into 7, 5, 7 and other activities. And then we did an amortization at the beginning of January of 3 million to 5 million. But the other parts, 757 stands for 14 million of them, 32 in the period of cash changes. So it is important to remember to note that. The other business is not more than 16 million or 19 million including these 5 parts. What we can see is that We can take a look at the next picture. As we mentioned, we have had this picture for a while, and partner activities and partner costs relate essentially to 757, and of course it varies over time, and at the same time we have constant activities going on together with them, and then you can say that the study that we have now started in February, it will ramp up, so it will maybe increase over time, but then it is financed for everything, except then that we support certain FTEs. For the other external clinical costs, which are the other candidates, we have kept it a little lower in recent periods, with a certain focus on 2011-2017. In general, it can be noted that both for the quarter and when we look a little forward, we see that we have achieved and made a very good cost reduction that started last year. We see that the results are running and we are careful with that. Vi har behållit personalen på en nivå på cirka 30 personer. Det är viktigt för oss för att kunna svara upp mot alla de här aktiviteterna som pågår. Både i form av dialoger, men också samarbete framöver och byggaktiviteter framöver. What can also be mentioned is that there will be some natural declines here during the year, which means that the numbers will decrease and the costs will decrease significantly. Next picture, please. With that said, we move on to what we announced yesterday and we are of course very happy and grateful for the support we have received from existing owners and new investors and the board and management. We will come back to that. Det vi vill göra är att stärka vår finansiella ställning så att vi kan möta de här och förädla de här dialogerna som vi har pågående och nå fram till något fint. Vi vill också göra lite mer på 11.17 framåt och så kommer vi att tala tillbaks en del på det lånet som vi har till Fennia och så har vi omförhandlat det så att det fortsätter och är förlängt så det kommer att finnas med oss även in i 2017. Nästa bild, tack. Som Kristina nämnde, så är det en företrädelseemission på 68 miljoner för transaktionskostnader, där vi har fått täckningsåtaganden och avsikter på upp till 91 %. Det är vi såklart väldigt tacksamma och glada för. Med det sagt, när det är avsikter, så är det så att delvis styrelse och ledning har varit i en tyst period until now when we release the Q1, so we have not been able to write with them, but we will do so that the figure, if you were to look at the proportion that is the participants, that is, those that we are going to take advantage of and those that are intentions, will increase here in the future. Not the percentage and the amount per se, but the importance therein. Then we have also said that depending on how the degree of coverage goes in the emissions and how well When our other shareholders set up, some parts of these tax returns can then roll over and can be used in an overdraft option, which we have a good view of. It can be up to 33.8 million, or 34. So in total, as Kristina mentioned, 102 million for transaction costs. I would also like to point out that it is the tax returns It is not to compare with any guarantees, but it is guaranteed. We are confident that we will be able to get in these slabs to represent. Then we hope for as good coverage as possible so that we can get up to 102. It is of course due to an extra stream that we have called on the 5th of June. to approve and make decisions about this, both the representative and the sub-committee, but also to approve the technical support that we have received from the board and the board, as you can see here, which is 8 million in total. So everyone in the board, everyone in the board is involved, including the two proposed people who will be elected here in the future, and we are very happy for that support. It has been an important part of our dialogue with investors and developers. Nästa bild där. Nu kom vi hit. Vi kom med en bild för långt. Vad ska vi använda pengarna till? Det är framför allt för att stärka vår position i de pågående samtal som vi har. Det är jätteviktigt. Det är en bredd i de samtalen. Vi är såklart jätteglada för att vi kan and a better position in these dialogues, because otherwise you are weak. Now we feel much stronger with this fine support, and we think we can use it in a very positive way. Then of course we have to take some of our other candidates, especially Elba17, a little forward, and then we have and we want to emphasize that the study is vital, but we have a number of FTEs and people who work as we stand for. And then we simply have other growth-related parts that we need to move forward. Then you can say that if we include the entire overhead option, or the emission, So 34 million will be added, and then we indicate here that in essence it is the same distribution of the money that we show here on the previous emission. Next picture, please. We have set a course in this emission at 1.20 and we think that is a very good indication that we have a good support from our existing owners and the new the new investors that come with us and we believe that it is very important for the company to have done this. Three old shares give the right to two new ones. We can reach up to 102 million as we said. 68 we feel safe with. Then we will see how much it will be of these 34. The extra vote is important to remember and we will have an indication of the termination period from June 11 to June 25. Vi räknar med att allt är klappat och klart runt 3 juli. Nästa sida, tack. Då lämnar jag över till Niklas.